MRNS - Marinus Pharmaceuticals, Inc.
| Previous Close | 3.0500 |
| Open | 3.0700 |
| Bid | 0.00 x 2900 |
| Ask | 0.00 x 2900 |
| Day's Range | 2.9500 - 3.1500 |
| 52 Week Range | 2.3600 - 10.5400 |
| Volume | 480,814 |
| Avg. Volume | 1,294,770 |
| Market Cap | 162.302M |
| Beta (3Y Monthly) | 5.09 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.87 |
| Earnings Date | Jul 30, 2018 - Aug 3, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 20.33 |
Insider Monkey•last monthHedge Funds Are Crazy About Marinus Pharmaceuticals Inc (MRNS)
Hedge funds and large money managers usually invest with a focus on the long-term horizon and, therefore, short-lived dips on the charts, usually don’t make them change their opinion towards a company. This time it may be different. During the first 6 weeks of the fourth quarter we observed increased volatility and small-cap stocks underperformed […]
- American City Business Journals•last month
Marinus Pharmaceuticals plans $45M stock sale
Based in Radnor, Marinus Pharmaceuticals is studying a potential treatment for postpartum depression and acute epilepsy.
- GlobeNewswire•last month
Marinus Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Marinus Pharmaceuticals, Inc. (MRNS) (“Marinus” or the “Company”) announced the pricing of an underwritten public offering of 12,000,000 shares of common stock at a public offering price of $3.75 per share. The total public offering size is expected to be $45.0 million, before deducting the underwriting discounts and commissions and other offering expenses payable by the Company. The Company has granted to the underwriters participating in the offering a 30-day option to purchase up to an additional 1,800,000 shares of common stock.
- Motley Fool•last month
Here's Why Marinus Pharmaceuticals Is Sinking Today
A secondary offering on the way isn't what investors wanted to hear.
- Benzinga•last month
The Daily Biotech Pulse: Legal Victory For Boston Scientific, Alder Gets New CFO, FDA Go-Ahead For BioXcel
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Dec. 11) Imprimis Pharmaceuticals Inc (NASDAQ: IMMY ) OvaScience ...
- GlobeNewswire•last month
Marinus Pharmaceuticals Announces Public Offering of Common Stock
Marinus Pharmaceuticals, Inc. (MRNS), (“Marinus” or the “Company”) today announced that it intends to offer and sell 12,000,000 shares of its common stock in an underwritten public offering. All of the shares in the offering are to be sold by Marinus. Jefferies LLC and Leerink Partners LLC are acting as joint bookrunning managers for the offering. Marinus also expects to grant the underwriters a 30-day option to purchase up to an additional 1,800,000 shares of common stock. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
- Benzinga•last month
Marinus Pharma's Postpartum Depression Candidate Aces Midstage Trials
A handful of micro-cap stocks were making moves Monday, with the release of clinical trial results being the catalyst. Marinus said the Phase 2 trials that evaluated intravenous and oral ganaxolone for women with postpartum depression, or PPD, produced positive results.
- GlobeNewswire•last month
Marinus Pharmaceuticals Announces Positive Ganaxolone Data in Women With Postpartum Depression
Marinus Pharmaceuticals, Inc. (MRNS) (“Marinus” or “Company”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy, depression and other neuropsychiatric disorders, today announced positive results from its Phase 2 clinical trials evaluating ganaxolone intravenous (IV) (the Magnolia Study) and oral (the Amaryllis Study) in women with postpartum depression (PPD). Based on these results, the Company is advancing both studies into the next phase of development to evaluate IV and oral dose regimens.
- GlobeNewswire•2 months ago
Marinus Pharmaceuticals Phase 2 Clinical Trial Data Show Long-term Effectiveness of Ganaxolone in Reducing Seizure Frequency in CDKL5 Deficiency Disorder Patients
Marinus Pharmaceuticals, Inc. (MRNS) (the “Company”, “Marinus”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that ganaxolone data from its Phase 2 clinical trial in pediatric genetic epilepsies, CDKL5 Deficiency Disorder (CDD) and PCDH19-related pediatric epilepsy (PCDH19 epilepsy) were presented at the American Epilepsy Society (AES) Annual Meeting in New Orleans on December 2 and 3, 2018.
- GlobeNewswire•2 months ago
Marinus Pharmaceuticals to Present Ganaxolone Clinical Trial Data in CDKL5 Deficiency Disorder and PCDH19-Related Epilepsy at AES
Marinus Pharmaceuticals, Inc. (MRNS) (the “Company”, “Marinus”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that two abstracts highlighting the results of clinical trials of ganaxolone in children with CDKL5 Deficiency Disorder (CDD) and PCDH19-related epilepsy have been selected for poster presentation at the American Epilepsy Society (AES) Annual Meeting in New Orleans on December 2 and 3, 2018.
- Insider Monkey•2 months ago
Granite Point Capital’s Returns, AUM, and Holdings
Warren Lammert founded Granite Point Capital, a long/short hedge fund with a focus on small-cap companies, in January 2004. The fund is headquartered in Boston, Massachusetts, and Mr. Lammert is its portfolio manager. Prior to launching his own fund, Warren Lammert honed his investment acumen for 14 years at Janus Capital Management LLC as a […]
- Zacks•3 months ago
Is the Options Market Predicting a Spike in Marinus Pharmaceuticals (MRNS) Stock?
Investors need to pay close attention to Marinus Pharmaceuticals (MRNS) stock based on the movements in the options market lately.
- GlobeNewswire•3 months ago
Research Report Identifies Oil States International, Brightcove, Electronics for Imaging, Cirrus Logic, Innoviva, and Marinus Pharmaceuticals with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
NEW YORK, Nov. 06, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- Associated Press•3 months ago
Marinus Pharmaceuticals: 3Q Earnings Snapshot
The Radnor, Pennsylvania-based company said it had a loss of 27 cents per share. Marinus Pharmaceuticals shares have dropped 38 percent since the beginning of the year. The stock has dropped 16 percent ...
- GlobeNewswire•3 months ago
Marinus Pharmaceuticals Provides Business Update and Third Quarter 2018 Financial Results
RADNOR, Pa., Oct. 29, 2018 -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (“Marinus” or “Company”), a biopharmaceutical company dedicated to the development of innovative.
- Simply Wall St.•4 months ago
What Kind Of Shareholders Own Marinus Pharmaceuticals Inc (NASDAQ:MRNS)?
A look at the shareholders of Marinus Pharmaceuticals Inc (NASDAQ:MRNS) can tell us which group is most powerful. Insiders often own a large chunk of younger, smaller, companies while huge Read More...
- ACCESSWIRE•4 months ago
Deals Pile Up as Big Biotech Looks to Capitalize on the Growing Market
HENDERSON, NV / ACCESSWIRE / September 20, 2018 / Small biotech companies have been receiving a ton of interest this year. Just last week, Boehringer Ingelheim's shopping spree continued with a €210m takeover of ViraTherapeutics, an oncolytic virus specialist it has been working with since 2016. Delcath Systems, Inc. (DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, has recently announced an amendment to its Registration trial in ocular melanoma liver metastases, a disease that has shown resistance to the new immunotherapies.
